No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 15.2x · 10Y median 77.8x · 26th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:02:14.817Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T14:02:14.817Z. Latest historical point 2026-05-14. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T14:02:14.817Z. Latest historical point 2026-05-14. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T14:02:14.817Z. Latest historical point 2026-05-14. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T14:02:14.817Z. Latest historical point 2026-05-14.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T14:02:14.817Z. Latest historical point 2026-05-14. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:02:14.817Z. Latest historical point 2026-05-14. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:02:14.817Z. Latest historical point 2026-05-14. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Keros Therapeutics, Inc. (KROS) stock was $11.47 as of Oct 6, 2026, 10:00 AM EDT, down 0.43% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -27.6% · 3-year avg -29.5%/yr · 5-year avg -22.0%/yr
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis.
Biotechnology · Lexington, MA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 4, 2026
29 days away
EPS Estimate
-0.96
Revenue Est.
$14.76M
Last Quarter Results
EPS
$-1.45
vs Estimate
$-1.24
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1KROS | $227.42M | $11.47 | -0.43% | -27.62% | -21.98% | N/A | N/A |
| 2MGNX | $233.28M | $3.67 | -2.65% | +111.04% | -28.42% | -18.75% | vs KROS |
| 3LYEL | $219.36M | $8.95 | -1.30% | -48.74% | -48.18% | N/A | vs KROS |
| 4ALEC | $218.72M | $1.97 | -1.01% | -39.91% | -39.17% | N/A | vs KROS |
| 5BIOA | $236.44M | $6.28 | -1.26% | +13.30% | N/A | N/A | vs KROS |
| 6CGEN | $217.95M | $2.31 | -0.22% | +41.48% | -18.39% | -9.42% | vs KROS |
forward FY estimate
N/A
$0.00
vs Estimate
$807143.00
Consensus Rating
Based on 6 analysts
Average Price Target
$19.83
+72.9% upside
Low
$16.00
Current
$11.47
High
$25.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-1.50 | $-0.94 | $-0.64 | 3 |
| Quarter ending Dec 2026 | $-2.22 | $-1.93 | $-1.68 | 4 |
| Quarter ending Mar 2027 | $-2.23 | $-2.23 | $-2.23 | 1 |
| Quarter ending Jun 2027 | $-1.65 | $-1.65 | $-1.65 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-6.20 | $-5.54 | $-4.85 | 5 |
| FY 2027 | $-8.71 | $-6.24 | $-3.75 | 5 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $384200.00 | $14.76M | $21.95M | 4 |
| Quarter ending Dec 2026 | $478571.00 | $478571.00 | $478571.00 | 4 |
| Quarter ending Mar 2027 | $433333.00 | $433333.00 | $433333.00 | 2 |
| Quarter ending Jun 2027 | $433333.00 | $433333.00 | $433333.00 | 2 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $1.19M | $15.56M | $22.74M | 5 |
| FY 2027 | $9.15M | $13.73M | $18.21M | 5 |
